The impact of artificial intelligence on drug discovery for neuropsychiatric disorders
EXCLI Journal · 03.07.2025 · 24 · 728-748
DOI: 10.17179/excli2025-8378 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 03.07.2025. Verfasst von Vickram Agaram Sundaram und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Saveetha School of Engineering, SIMATS, Chennai, 602105, India. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Artificial intelligence (AI) and machine learning (ML) are transforming medication discovery, particularly in neuropsychiatric illnesses, where traditional drug research presents major obstacles. This paper looks at how artificial intelligence might help advance neuropsychiatric medication development, with an emphasis on early-stage research, drug design, and clinical diagnostics. This review discusses AI's contribution to understanding the blood-brain barrier and its link with the central nervous system, which is an important aspect of medication efficacy in neuropsychiatric treatments. AI-facilitated de novo drug design, using predictive algorithms and deep learning models, speeds up the discovery of new medicinal molecules. AI is employed in brain imaging and diagnosis, boosting the accuracy with which neuropsychiatric diseases are identified. BBB permeability prediction is one of the most important uses of AI in drug discovery, as it improves the selection of CNS-active drugs. Additionally, AI is transforming treatment techniques for neurodevelopmental disorders and assisting in the discovery of novel antidepressant medications through data-driven methodologies. Despite these accomplishments, AI-driven drug discovery still has several constraints, such as data biases, regulatory barriers, and ethical issues. Overcoming these restrictions will be critical to unlocking AI's full potential in neuropsychiatric research. This paper concludes with several future possibilities and opportunities, such as incorporating AI into personalized medicine using sophisticated neural network models and multimodal data fusion techniques. This might increase treatment choices for certain conditions by fine-tuning AI approaches. This paper presents a perspective on AI as a highly transformative instrument for influencing neuropsychiatric drug development, as well as an emerging field that has the potential to impact the modern idea of pharmacology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biotechnology, Saveetha School of Engineering, SIMATS, Chennai, 602105, India.
- Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, India.
- Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
Zitieren
APA
Agaram Sundaram, V., Saravanan, B., Sowndharya Balamurugan, B., Muthu Chinnakannu Marimuthu, M., Munjal, K., & Chopra, H. (2025). The impact of artificial intelligence on drug discovery for neuropsychiatric disorders. EXCLI Journal, 24, 728-748. https://doi.org/10.17179/excli2025-8378
Vancouver
Agaram Sundaram V, Saravanan B, Sowndharya Balamurugan B, Muthu Chinnakannu Marimuthu M, Munjal K, Chopra H. The impact of artificial intelligence on drug discovery for neuropsychiatric disorders. EXCLI Journal. 2025;24:728-748. doi:10.17179/excli2025-8378
BibTeX
@article{AgaramSundaram2025,
author = {Agaram Sundaram, Vickram and Saravanan, Bharath and Sowndharya Balamurugan, Bhavani and Muthu Chinnakannu Marimuthu, Mathan and Munjal, Kavita and Chopra, Hitesh},
title = {The impact of artificial intelligence on drug discovery for neuropsychiatric disorders},
journal = {EXCLI Journal},
year = {2025},
volume = {24},
pages = {728--748},
doi = {10.17179/excli2025-8378}
}
EUVIMED